Stero Biotechs

STERO, founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy. STERO’s extremely wide coverage patent (CBD from any source, in any combination, any dosage, in any delivery system, all for more than 130 diseases by name) was Issued in the US on August 2018 and is pending in main countries around the world. Stero currently has 3 ongoing clinical trials, 2 phase 2a clinical trials in Crohn's disease, and in Chronic Urticaria (Hives), 1 phase 1/2 clinical trial treating severe covid-19 patients, all covered by Stero’s IP & pursuing the FDA drug route, with more in the pipeline.